Recombinant RSV (Palivizumab Biosimilar) antibody

Catalog No. ABIN7597894

The Humanized Chimeric anti-RSV (Palivizumab Biosimilar) antibody has been validated for . It is suitable to detect RSV (Palivizumab Biosimilar) in samples from Human respiratory syncytial virus A.

Quick Overview for Recombinant RSV (Palivizumab Biosimilar) antibody (ABIN7597894)

Target: RSV (Palivizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human respiratory syncytial virus A

Host: Humanized

Clonality: Chimeric

Conjugate: This RSV (Palivizumab Biosimilar) antibody is un-conjugated

Application: Please inquire

Grade: Research Grade

Product Details anti-RSV (Palivizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Research Grade Palivizumab Biosimilar Antibody

Specificity: F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Purification: Protein A or G purified from cell culture supernatant.

Purity: >95 % by SDS-PAGE.

Isotype: IgG1, kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 2.47 mg/mL

Buffer: 0.01M PBS, pH 7.4.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Expiry Date: 12 months

Target Details for RSV (Palivizumab Biosimilar)

Target: RSV (Palivizumab Biosimilar)

Alternative Name: Palivizumab Biosimilar

Target Type: Biosimilar

Background: F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

UniProt: P03420

CAS-No: 188039-54-5